Next |
home / stock / celg / celg message board
Subject | By | Source | When |
---|---|---|---|
Better Buy: Celgene vs. Gilead Sciences | BottomBounce | investorshub | 10/24/2020 12:38:18 PM |
Sorry, dont know | patrickjishere | investorshub | 02/18/2019 10:31:14 PM |
Do you or anyone here know the tax | rosemountbomber | investorshub | 02/18/2019 10:08:04 PM |
Advances in Cancer Drugs Fuel Deal -- WSJ | TheFinalCD | investorshub | 01/04/2019 2:09:31 PM |
Yep, I like $BMY and the deal. | patrickjishere | investorshub | 01/03/2019 7:24:29 PM |
Good call, a good analyst always starts with | Johnny_C | investorshub | 01/03/2019 2:53:49 PM |
I thought I was a genius when I | patrickjishere | investorshub | 12/29/2018 7:06:14 PM |
I dont know. But, there was some dialog | biotech_researcher | investorshub | 12/29/2018 10:29:18 AM |
Now is the time to buy for a | patrickjishere | investorshub | 12/28/2018 7:58:06 PM |
$50s for Celgene? | biotech_researcher | investorshub | 12/21/2018 5:20:14 PM |
https://www.mdmag.com/medical-news/ashish-khanna-md-checking-in-on-angiotensin-2 | StockLearner2011 | investorshub | 12/07/2018 11:57:20 AM |
Something is wrong with Celgene, and it is | biotech_researcher | investorshub | 11/20/2018 4:40:05 PM |
Celgene Corp $CELG Chart Signals Trouble | ITMS | investorshub | 09/19/2018 5:03:16 PM |
As the old saying goes, there is usually | biotech_researcher | investorshub | 08/06/2018 1:39:33 PM |
7 Companies We'd Buy and Hold for the | BottomBounce | investorshub | 07/03/2018 3:08:21 AM |
Breakout Alert: Celgene $CELG | ITMS | investorshub | 06/19/2018 7:35:37 PM |
They need to fire Mark Alles, CEO, to | biotech_researcher | investorshub | 05/18/2018 2:19:02 PM |
Now I know why they call it the | biotech_researcher | investorshub | 05/17/2018 10:54:20 AM |
Surprised that the CEO of Celgene, Mark Alles, | biotech_researcher | investorshub | 05/10/2018 1:59:49 PM |
$CELG falling knife damn | Pennies_Envy | investorshub | 05/08/2018 5:03:53 PM |
News, Short Squeeze, Breakout and More Instantly...
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...